Parkinson Disease Psychosis

This program may include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

PD and PDP: Overview

Recognizing PDP

Recognizing PDP (cont)

Hallucinations and Delusions: Hallmarks of PDP

Are You Seeing Things? Queries for the Patient

Steps Before Prescribing an Antipsychotic Patient Assessment

Considerations When Prescribing an Antipsychotic

Pimavanserin: 5-HT2A Inverse Agonist

Improving Collaborative Care

Medications Used for PDP

FDA Pimavanserin Analysis No New or Unexpected Risks

Challenges of PDP Care

Monitoring Pimavanserin Use

Concluding Remarks

Abbreviations